Vadimezan (DMXAA)是DT-diaphorase的竞争性抑制剂，K_i为20 μM，IC₅₀为62.5 μM。Vadimezan也是一种血管破坏剂，可破坏肿瘤血管系统，具有潜在的抗肿瘤活性。

参考文献

[1] Phillips RM. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Biochem Pharmacol. 1999 Jul 15;58(2):303-10. doi: 10.1016/s0006-2952(99)00092-1(IF:4.825).

[2] Shirey KA, Nhu QM, Yim KC, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7. doi: 10.1189/jlb.0410216(IF:4.012).

-25~-15℃保存，有效期3年。